USPTO Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies

ONK Therapeutics Ltd announced that the US Patent and Trademark Office has granted its licensed patent that covers CISH knockout in natural killer (NK) cells, irrespective of the source of the NK cells, including, for example, human cord blood-derived and human iPSC-derived cells